SomaLogic

company

About

SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$375M
Industries
Biotechnology,Health Care,Health Diagnostics,Medical Device
Founded date
Jan 1, 2000
Number Of Employee
251 - 500
Operating Status
Active
Stock Symbol
nasdaq:SLGC
Legal Name
SomaLogic, Inc.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.

SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
18
$1.58B
SomaLogic has raised a total of $1.58B in funding over 2 rounds. Their latest funding was raised on Sep 1, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 1, 2021 Post-IPO Equity $375M 11 Detail
Sep 1, 2021 IPO $630M Detail
Dec 23, 2020 Series A $81M 11 Detail
Nov 25, 2020 Series A $121M 11 Casdin Capital Detail
Jan 3, 2018 Series Unknown $200M 7 iCarbonX Detail

Employee Profiles

Number of Employee Profiles
15
SomaLogic has 15 current employee profiles, including Board member Eli Casdin
Board member
Executive
Executive
Executive
Advisor

Acquisition

SomaLogic has acquired 1 organizations. Their most recent acquisition was Palamedrix on Jul 26, 2022. They acquired Palamedrix for $35M.

Date Company Name
Industry Acquisition Type Price
Jul 26, 2022 Palamedrix
Biotechnology acquisition $ 35M Detail